Belinda Cairns

Multimeric Biotherapeutics (United States) — United States

Medicine · Health Sciences

14h-index1.4kcitations37works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(16), Cancer Cells and Metastasis(9), Mass Spectrometry Techniques and Applications(8), Immunotherapy and Immune Responses(6), T-cell and B-cell Immunology(5)

Publications37 total

Abstract CT044: Preliminary activity and safety of OBT076 in patients with CD205 positive solid tumors: Results from the phase 1b part B expansion cohort
Cancer Research·2025
Abstract LB429: Discovery and identification of a novel cancer associated fibroblast target using Oxford Biotherapeutics (OBTs) OGAP discovery platform
Cancer Research·2024
Table S1 from Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity
2023Open Access
Data from Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity
2023Open Access
Figure S5 from Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity
2023Open Access
Figure S3 from Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity
2023Open Access
Figure S5 from Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity
2023Open Access
Figure S2 from Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity
2023Open Access
Figure S4 from Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity
2023Open Access
Figure S1 from Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity
2023Open Access
Table S1 from Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity
2023Open Access
Figure S1 from Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity
2023Open Access
Data from Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity
2023Open Access
Figure S2 from Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity
2023Open Access
Figure S6 from Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity
2023Open Access
Figure S3 from Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity
2023Open Access
Figure S6 from Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity
2023Open Access
Figure S4 from Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity
2023Open Access
Chemoradiation therapy alters the PD-L1 score in locoregional recurrent squamous cell carcinomas of the head and neck
Oral Oncology·2022· 11 citedOpen Access
An anti-PD-1–GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy
Nature Cancer·2022· 66 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Sun K. Ho(18), Mien Sho(18), Archana Thakur(18), C.M. Forsyth(18), Mengli Xiong(18), Siu Sze Tan(18), Enrico L. DiGiammarino(18), Li Zhou(18), Melvin Fox(18), Yoshiko Akamatsu(18), Diane Hollenbaugh(18), Hamsell M. Alvarez(18), Josue Samayoa(18), Debra T. Chao(18), Zhenghai Xu(17), David B. Powers(17), Vivian Zhao(16), Lawrence Chinn(4), Harold Thibodeaux(3), Robert Gerlai(3)